Spots Global Cancer Trial Database for Synovial Sarcoma Registry / Biospecimen Repository

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Synovial Sarcoma Registry / Biospecimen Repository

Official Title: Synovial Sarcoma Registry and Biospecimen Repository

Study ID: NCT05910307

Conditions

Synovial Sarcoma

Interventions

Study Description

Brief Summary: The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.

Detailed Description: This study will enroll patients with a diagnosis of Synovial Sarcoma. Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records. At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes. Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study. Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs). Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.